Nektar Therapeutics (NKTR) Prepaid Assets (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Prepaid Assets of $20.4 million for Q1 2026, up 81.16% year-over-year from $11.3 million in Q1 2025, and little changed quarter-over-quarter from $20.5 million in Q4 2025.
Nektar Therapeutics (NKTR) Prepaid Assets (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Prepaid Assets history runs 17 years deep, the most recent figure standing at $20.4 million for Q1 2026.
- In Q1 2026, Prepaid Assets rose 81.16% year-over-year to $20.4 million; the TTM figure through Mar 2026 stood at $20.4 million (up 81.16% YoY), while the FY2025 annual figure was $20.5 million, up 238.18% from the prior year.
- Prepaid Assets for Q1 2026 stood at $20.4 million, roughly flat from $20.5 million in the prior quarter.
- The five-year high for Prepaid Assets was $22.5 million in Q3 2022, with the low at $6.1 million in Q4 2024.
- The 5-year median for Prepaid Assets is $11.0 million (2023), against an average of $13.3 million.
- The sharpest annual moves came in 2023 and 2025: Prepaid Assets plunged 59.87% in 2023, then jumped 238.18% in 2025.
- Nektar Therapeutics' Prepaid Assets stood at $15.8 million in 2022, then slumped by 38.14% to $9.8 million in 2023, then tumbled by 37.97% to $6.1 million in 2024, then surged by 238.18% to $20.5 million in 2025, then decreased by 0.38% to $20.4 million in 2026.
- Business Quant data shows NKTR's Prepaid Assets at $20.4 million in Q1 2026, $20.5 million in Q4 2025, and $11.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.44 Mn |
| Dec 31, 2025 | 20.51 Mn |
| Sep 30, 2025 | 11.15 Mn |
| Jun 30, 2025 | 10.66 Mn |
| Mar 31, 2025 | 11.28 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Sep 30, 2024 | 8.93 Mn |
| Jun 30, 2024 | 8.29 Mn |
| Mar 31, 2024 | 10.74 Mn |
| Dec 31, 2023 | 9.78 Mn |
| Sep 30, 2023 | 9.03 Mn |
| Jun 30, 2023 | 9.60 Mn |
| Mar 31, 2023 | 11.01 Mn |
| Dec 31, 2022 | 15.81 Mn |
| Sep 30, 2022 | 22.51 Mn |
| Jun 30, 2022 | 19.25 Mn |
| Mar 31, 2022 | 20.83 Mn |
| Dec 31, 2021 | 23.33 Mn |
| Sep 30, 2021 | 20.73 Mn |
| Jun 30, 2021 | 12.60 Mn |